Peer-Reviewed Publication
Clin Breast Cancer2026;26(8):14-20.August 1, 2026Journal Article
Refining Stratification in Premenopausal Node-Positive HR+/HER2- Breast Cancer With a Novel AI-Based Test.
Jailan Elayoubi1, Cerise Tang2, Kathryn J Ruddy3, Khalil Choucair1, Kevin Kalinsky4, Katarzyna Pogoda5, Francisco J Esteva6, Jad M Abdelsattar7, Virginia F Borges8, Ken Zeng2, Joseph Cappadona2, Bartosz Machura2, Dhruva Biswas2, Krzysztof J Geras2, Jan Witowski9
1Department of Hematology and Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, MI.
2Ataraxis AI, New York, NY.
3Department of Oncology, Mayo Clinic, Rochester, MN.
4Winship Cancer Institute of Emory University, Atlanta, GA.
5Department of Breast Cancer and Reconstructive Surgery, National Research Institute of Oncology in Warsaw, Warsaw, Poland.
6Division of Hematology/Oncology, Northwell Health Cancer Institute, Lenox Hill Hospital, New York, NY.
7University of Arizona College of Medicine, Tucson, AZ.
8University of Colorado Anschutz Medical Campus, Aurora, CO.
9Ataraxis AI, New York, NY. Electronic address: jan.witowski@ataraxis.ai.
Abstract
BACKGROUND: Genomic assays are considered the standard of care for stratification and chemotherapy benefit prediction in postmenopausal women with breast cancer. However, clinical trials indicate that these tools have limited utility for premenopausal women, especially when considering chemotherapy de-escalation in node-positive cases. Here, we evaluate Ataraxis Breast RISK (ATX), an artificial in…
Create a free account to keep reading
Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.
Want unlimited research access? See Pro plans